<DOC>
	<DOCNO>NCT02648386</DOCNO>
	<brief_summary>Erectile dysfunction ( ED ) one common complication men rectal cancer treatment . The purpose study assess safety efficacy autologous bone marrow mononuclear cell ( BMMCs ) allogeneic human umbilical cord-derived mesenchymal stem cell ( HUC-MSCs ) combine NeuroRegen scaffold transplantation men erectile dysfunction rectal cancer treatment .</brief_summary>
	<brief_title>Stem Cell Therapy Combined With NeuroRegen Scaffoldâ„¢ Patients With Erectile Dysfunction After Rectal Cancer Surgery</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>1 . Diagnosed local rectal cancer , within 12cm anus . 2 . Male , 2065 year old . 3 . IIEF5 score &gt; 21 . 4 . No obvious abnormal external genitalia , testis , epididymis spermatic cord . 5 . Have consistent partner willing engage sexual activity twice per month study . 6 . Signed informed consent . 7 . Recently take drug affect sexual function ( androgen replacement drug , PDE5i Chinese patent medicine , etc. ) . 1 . Suffering hypertension diabetes . 2 . In investigator judgment , clinical significance penis abnormality , receive penile prosthesis implantation surgery . 3 . Patient 's partner try conceive trial period . 4 . Exposure investigational drug procedure within 1 month prior study entry enrol concurrent study may confound result study . 5 . Geographically inaccessible followup visit require protocol want treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>